Global clinical trial markets have recently faced unique challenges in participant recruitment, due to environmental impacts of the Covid pandemic. Through lockdowns, high rates of infection and vaccine rollouts, clinical trial providers around the world have had to navigate and adjust to uncertain and ongoing changes in participant markets, and the associated change in behavior. Australia's main challenge has been the extended international border closure to tourists.
Operating three clinical units across Australia (2) and the USA (1), Nucleus Network is in a unique position to understand and discuss these changes in participant behavior and subsequent recruitment challenges faced by Phase 1 clinical trial units across different countries.
Considering these challenges, this webinar will discuss the recruitment outlook for Phase 1 clinical trials in Australia in the new Covid-normal world. Investing heavily in extensive data analysis and research, hear how Nucleus Network has developed an innovative recruitment approach underpinned by key strategies and additional infrastructure to enhance recruitment.
Register to hear discussions covering the stabilized participant market, the introduction of satellite sites to access a broader population of participants, and more than 18 months of new participant market education. Data and current recruitment trends will be examined to provide the audience with a better understanding of the current and future Australian market and the innovative strategies being deployed to ultimately ensure that as we transition to open borders, Australia continues to remain a destination of choice for the conduct of Phase 1 clinical trials.
Key Learning Objectives
- The recruiting outlook for Australia in 2022, as the world transitions into a post-pandemic normal market.
- Understanding and educating the covid-normal participant using research, data and innovative strategies.
- The role of collaboration between sponsors and providers in opening pathways to recruitment.
- Optimizing systems and processes to increase and stabilize lead–to-dose conversion rates.
Target Audience
- C-suite
- CEO
- Chief Technology Officer (CTO)
- Chief Medical Officer (CMO)
- Medical Officer
- Heads of development
- Heads of research
- Medical Researcher
- Operations Personnel
